Leonard Charles Bailey

Leonard Charles Bailey

Auto-generated profile, based on publicly available information

Leonard Charles Bailey

Applied Clinical Research Center, Departments of Pediatrics and Biomedical and Health Informatics,Children’s Hospital of Philadelphia, PA, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in JAMA Pediatrics
Verified
Journal Article
Open access
PDF file
LBL. Charles Bailey
L. Charles Bailey
HRHanieh Razzaghi
Hanieh Razzaghi
EBEvanette K. Burrows
Evanette K. Burrows
HBH. Timothy Bunnell
H. Timothy Bunnell
PCPeter E. F. Camacho
Peter E. F. Camacho
CFChristopher B. Forrest
Christopher B. Forrest
The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in November 2019 and by March 2020 was pandemic.1 Reported cases of coronavirus disease 2019 (COVID-19) have exceeded 8.5 million in the United States2 and are declining in some regions and rising in others.3 Although several syndromic presentations have been reported, there is a lack of systematic information documenting the effects of SARS-CoV-2 on children, adolescents, and young adults.

8 January 2018 in Journal of Medical Internet Research
Verified
Journal Article
Open access
CPCharles A Phillips
Charles A Phillips
ALAllison Barz Leahy
Allison Barz Leahy
YLYimei Li
Yimei Li
MSMarilyn M. Schapira
Marilyn M. Schapira
LBL. Charles Bailey
L. Charles Bailey
RMRaina M. Merchant
Raina M. Merchant
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet

1 February 2024 in Annals of Internal Medicine
Verified
Journal Article
Closed access
QWQiong Wu
Qiong Wu
JTJiayi Tong
Jiayi Tong
BZBingyu Zhang
Bingyu Zhang
DZDazheng Zhang
Dazheng Zhang
JCJiajie Chen
Jiajie Chen
YCYong Chen
Yong Chen
The efficacy of the BNT162b2 vaccine in pediatrics was assessed by randomized trials before the Omicron variant's emergence. The long-term durability of vaccine protection in this population during the Omicron period remains limited. To assess the effectiveness of BNT162b2 in preventing infection and severe diseases with various strains of the SARS-CoV-2 virus in previously uninfected children and adolescents. Comparative effectiveness research accounting for underreported vaccination in 3 study cohorts: adolescents (12 to 20 years) during the Delta phase and children (5 to 11 years) and adolescents (12 to 20 years) during the Omicron phase. A national collaboration of pediatric health systems (PEDSnet). 77 392 adolescents (45 007 vaccinated) during the Delta phase and 111 539 children (50 398 vaccinated) and 56 080 adolescents (21 180 vaccinated) during the Omicron phase. First dose of the BNT162b2 vaccine versus no receipt of COVID-19 vaccine. Outcomes of interest include documented infection, COVID-19 illness severity, admission to an intensive care unit (ICU), and cardiac complications. The effectiveness was reported as (1-relative risk)*100, with confounders balanced via propensity score stratification. During the Delta period, the estimated effectiveness of the BNT162b2 vaccine was 98.4% (95% CI, 98.1% to 98.7%) against documented infection among adolescents, with no statistically significant waning after receipt of the first dose. An analysis of cardiac complications did not suggest a statistically significant difference between vaccinated and unvaccinated groups. During the Omicron period, the effectiveness against documented infection among children was estimated to be 74.3% (CI, 72.2% to 76.2%). Higher levels of effectiveness were seen against moderate or severe COVID-19 (75.5% [CI, 69.0% to 81.0%]) and ICU admission with COVID-19 (84.9% [CI, 64.8% to 93.5%]). Among adolescents, the effectiveness against documented Omicron infection was 85.5% (CI, 83.8% to 87.1%), with 84.8% (CI, 77.3% to 89.9%) against moderate or severe COVID-19, and 91.5% (CI, 69.5% to 97.6%) against ICU admission with COVID-19. The effectiveness of the BNT162b2 vaccine against the Omicron variant declined 4 months after the first dose and then stabilized. The analysis showed a lower risk for cardiac complications in the vaccinated group during the Omicron variant period. Observational study design and potentially undocumented infection. This study suggests that BNT162b2 was effective for various COVID-19-related outcomes in children and adolescents during the Delta and Omicron periods, and there is some evidence of waning effectiveness over time. National Institutes of Health.

17 June 2019 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
CPCharles A. Phillips
Charles A. Phillips
HRHanieh Razzaghi
Hanieh Razzaghi
TATaylor Aglio
Taylor Aglio
MMMichael McNeil
Michael McNeil
MSMikaela Salvesen‐Quinn
Mikaela Salvesen‐Quinn
LBL. Charles Bailey
L. Charles Bailey

19 January 2022 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
CPCharles A. Phillips
Charles A. Phillips
LBLamia P. Barakat
Lamia P. Barakat
BPBrad H. Pollock
Brad H. Pollock
LBL. Charles Bailey
L. Charles Bailey
RBRinad S. Beidas
Rinad S. Beidas

7 May 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
PLPi-i Lin
Pi-i Lin
SRSheryl Rifas‐Shiman
Sheryl Rifas‐Shiman
JMJohn Merriman
John Merriman
JPJoshua Petimar
Joshua Petimar
HYHan Yu
Han Yu
JBJason P. Block
Jason P. Block
Background: Guidelines for the use of antihypertensives changed in 2014 and 2017. To understand the effect of these guidelines, we examined trends in antihypertensive prescriptions in the United States from 2010 to 2019 using a repeated cross‐sectional design. Methods and Results: Using electronic health records from 15 health care institutions for adults (20–85 years old) who had ≥1 antihypertensive prescription, we assessed whether (1) prescriptions of beta blockers decreased after the 2014 Eighth Joint National Committee (JNC 8) report discouraged use for first‐line treatment, (2) prescriptions for calcium channel blockers and thiazide diuretics increased among Black patients after the JNC 8 report encouraged use as first‐line therapy, and (3) prescriptions for dual therapy and fixed‐dose combination among patients with blood pressure ≥140/90 mm Hg increased after recommendations in the 2017 Hypertension Clinical Practice Guidelines. The study included 1 074 314 patients with 2 133 158 prescription episodes. After publication of the JNC 8 report, prescriptions for beta blockers decreased (3% lower in 2018–2019 compared to 2010–2014), and calcium channel blockers increased among Black patients (20% higher in 2015–2017 and 41% higher in 2018–2019, compared to 2010–2014), in accordance with guideline recommendations. However, contrary to guidelines, dual therapy and fixed‐dose combination decreased after publication of the 2017 Hypertension Clinical Practice Guidelines (9% and 11% decrease in 2018–2019 for dual therapy and fixed‐dose combination, respectively, compared to 2015–2017), and thiazide diuretics decreased among Black patients after the JNC 8 report (6% lower in 2018–2019 compared to 2010–2014). Conclusions: Adherence to guidelines on prescribing antihypertensive medication was inconsistent, presenting an opportunity for interventions to achieve better blood pressure control in the US population.